Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 47Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31trastuzumab deruxtecan 27Specimen Handling 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18Biopsy 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × flt3 ligand protein × Clear all
NCT05029999 2025-08-13

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

University of Texas Southwestern Medical Center

Phase 1 Recruiting
30 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡